312624-65-0

Basic information

• Product Name: FMOC-ALPHA-ME-LEU-OH
• Synonyms: FMOC-ALPHA-ME-LEU-OH;Fmoc-a-Me-Leu-OH;Fmoc-alpha-methyl-L-leucine;FMoc-alphaMe-L-Leu-OH;Fmoc-α-Me-L-Leucine;(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2,4-dimethylpentanoic acid;(2S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-2,4-dimethylpentanoic acid;(9H-Fluoren-9-yl)MethOxy]Carbonyl Alpha-Methyl-Leu-OH
• CAS NO: 312624-65-0
• Molecular Formula: C22H25NO4
• Molecular Weight: 367.44
• Product Categories: α-Methyl Amino Acids
• Mol File: 312624-65-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 562.652°C at 760 mmHg
• Flash Point: 294.082°C
• Appearance: /
• Density: 1.19g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.578
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.95±0.41(Predicted)
• CAS DataBase Reference: FMOC-ALPHA-ME-LEU-OH(CAS DataBase Reference)
• NIST Chemistry Reference: FMOC-ALPHA-ME-LEU-OH(312624-65-0)
• EPA Substance Registry System: FMOC-ALPHA-ME-LEU-OH(312624-65-0)

Safety Data

• Hazard Codes: O,Xn,N
• Statements: 8-22-50/53
• Safety Statements: 60-61
• TSCA: No
• Hazardous Substances Data: 312624-65-0(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C22H25NO4/c1-14(2)12-22(3,20(24)25)23-21(26)27-13-19-17-10-6-4-8-15(17)16-9-5-7-11-18(16)19/h4-11,14,19H,12-13H2,1-3H3,(H,23,26)(H,24,25)/t22-/m0/s1

Upstream product

• 865468-88-8 C₂₂H₂₃NO₄ 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 105743-53-1 (S)-2-amino-2,4-dimethylpentanoic acid 

Relevant articles and documents

Synthetic Modification within the rPRL Region of Apelin Peptides: Impact on Cardiovascular Activity and Stability to Neprilysin and Plasma Degradation

Apelin is an important mammalian peptide hormone with a range of physiological roles, especially in the cardiovascular system. The apelinergic system is a promising target for treatment of disease, but this remains to be realized due to rapid proteolysis of apelin-derived peptides by proteases, including neprilysin (NEP). The synthetic analogues modified within the NEP degradation site ( RPRL motif) showed improved in vitro proteolytic stability while maintaining receptor-binding affinities, with three candidate peptides retaining full cardiovascular activities for potential therapeutic application. Many such analogues proved physiologically inactive even with relatively conservative modifications, highlighting the importance of this region for full agonist activity of this peptide hormone.